Search
# Popular search #
0%
# Popular search #
Stock Code
603087.SHGan & Lee Pharmaceuticals' Fourth-generation Weekly Insulin Preparation GZR4 Completed the First Subject Administration in Phase I Clinical Trial
Gan & Lee Pharmaceuticals Announces Approval of Insulin Aspart in Kazakhstan
Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for the innovative once-weekly ultra-long-acting insulin, GZR4
Gan & Lee Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trials of GZR18
Gan & Lee Pharmaceuticals' Insulin Pen and the Pen Needle have been listed in Brazil
Gan & Lee Pharmaceuticals Announces IND Clearance by NMPA for the Ultra-Long Acting Insulin GZR4
To be a world-class pharmaceutical company with focus on global business development
Our products have been approved in 18 countries
Our products have been exported to 14 countries
Our products have been studied in clinical trials in 12 countries
Our products have been approved in 18 countries
Our products have been exported to 14 countries
Our products have been studied in clinical trials in 12 countries
This website uses cookies to give users like yourself the best possible content and experience. For more information about your choices regarding cookies, please review our Privacy Policy .
The site you are about to visit is maintained by a third party who is responsible for its content.
This link is provided on the Gan & Lee website as a service to our visitors. Gan & Lee is not responsible for the privacy policy of any third-party websites. Gan & Lee encourages visitors to read the privacy policy of every website that you may visit.
